EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR).
did not meet its primary endpoint of objective response rate (ORR).
did not meet its primary endpoint of objective response rate (ORR).
did not meet its primary endpoint of objective response rate (ORR).
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR).
did not meet its primary endpoint of objective response rate (ORR).
did not meet its primary endpoint of objective response rate (ORR).
did not meet its primary endpoint of objective response rate (ORR).
うーん。。。